Good morning, everyone, and how are you today? This will be an abbreviated session, since the Thanksgiving holiday is approaching on this side of the pond. Nonetheless, we are keeping busy. For starters, we are downing that mandatory cup of stimulation - and will certainly reach for still more as the day wears on so that we may tidy up the Pharmalot corporate campus for an influx of VIPs. Meanwhile, here are some tidbits. Catch you soon...
Celgene Halts Prostate Cancer Study For Revlimid (Reuters)
Pharmasset Founder Says Gilead Missed A Bargain Years Ago (Reuters)
Cholesterol Drugs Remain Safe After A Decade Of Use: Study (Reuters)
Ongoing Shortage Of ADHD Drugs Vexes Parents (NPR Shots)
Lilly CEO Ponders The R&D Crisis (Xconomy)
Is San Diego No Longer A Biotech Hot Spot? (San Diego Union-Tribune)
Reckitt Fined $32M By Germany For Price Fixing (Reuters)
EDITOR'S NOTE: Please check this post for updates throughout the morning
1 Comment
'Interesting' quote from the Pharmasset founder .....
"The philosophy is very simple. Good drugs save lives and a major side effect is they can also make you rich," he added.